In another Phase III randomized clinical trial (CheckMate 037) nivolumab demonstrated a higher percentage of overall response rate (ORR) as compared to investigator’s choice chemotherapy in patients with metastatic melanoma who experienced disease progression following anti-CTLA-4 or BRAF inhibitor treatment (31.7% vs 10.6%) [45]. Here, BRAF is linked to metastatic melanoma.